Here we present the first reported case of three-dimensional CT-guided salvage brachytherapy of recurring colorectal cancer in the pelvis after failed radiation therapy, total colectomy, and chemotherapy. Initial CEA was 67.0 ng/mL and tumor volume 93 cm 3 with no metastasis outside the pelvis. A total of 333 seeds of Iodine-125 were delivered to the entire target, with dosage of 150 to 200 Gy as calculated by post-implant CT dosimetry with Varian MMS software. CEA 12 months after implant decreased to 5.7 ng/mL. Clinical and biochemical results are encouraging; however long-term data in a greater universe of patients are required.
Introduction
Treatment options for patients with recurrent colorectal cancer in the pelvis who have failed radical colectomy, external beam radiation therapy (EBRT), and chemotherapy are limited. Patients with large recurrent colorectal tumors who have failed radical surgery (total colectomy) and EBRT are not candidates for salvage surgery. Furthermore, these patients are not candidates for second treatment with EBRT. Intraoperative salvage brachytherapy with I-125 seeds for recurrent colorectal cancer in the pelvis and paraortics has been reported, with poor prognoses in patients with large tumors (1).
We present the first reported case of salvage permanent percutaneous interstitial implant with a 3-dimensional CT-guided stereotactic posterior approach using I-125 seeds to treat a recurrent large nonresectable coloectal cancer in the pelvis in a patient who failed radical colectomy, radiation therapy, and chemotherapy. The low dose rate, low photon energy, and high attenuation of I-125 seeds facilitates the treatment of large volume tumors while protecting the adjacent organs.
Our experience in treating large volume tumors of the prostate with three-dimensional CT-guided stereotactic brachytherapy has been reported. (2). In addition, we have treated over 50 patients with localized prostate cancer with salvage brachytherapy after failed external beam radiation therapy or brachytherapy.
Case Study
In 1983 at age of 17 years the patient underwent colectomy for familial colorectal cancer. In 1995 he developed local recurrence at the ileorectal anastomosis and underwent second surgery and chemotherapy. In 1998 the patient had local recurrence with stricture of the ileorectal anastomosis. He was treated with radi-Panos G. Koutrouvelis, M.D.
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Vienna, VA 22182, USA ation therapy (54 Gy to the pelvis), total colectomy with perineal resection and permanent ileostomy, and chemotherapy (5-FU, leukovorin). In September 2000 the patient complained of pelvic pain and underwent biopsy that revealed extensive recurrence in the pelvis. Because of the previous radiation therapy with external beam radiation, a second external beam radiation was not feasible. The large size of tumor invading the prostate, the fat tissue in the mid-line of the presacral area in the pelvis, and previous radiation therapy prevented salvage surgery. The tumor was 93 cm 3 .
Staging
CT of the thorax, abdomen and pelvis was performed. CT of the upper abdomen revealed no evidence of periaortic lymphadenopathy. The liver was normal. The CT of the pelvis revealed recurrent infiltrating cancer into the posterior wall of the prostate and extending into the fat tissue of the pre-sacral area (1, 2). A bone scan and MRI of the upper abdomen was normal showing no evidence of distal metastasis. The patient's CEA was 67 ng/mL. In spite of its large size, the tumor had local invasion along the location of the rectosigmoid and did not spread systemically throught the lymphatic or hematogenous route.
A detailed 3-D stereotactic CT-guided core biopsy was performed from the distal portion of the lesion to its most proximal portion. The patient was placed in prone position on the CT table. The 3-D stereotactic system was placed over the gluteal area. The 3-D stereotactic template was adjusted so that the needle path would not be obstructed by the sacrum. A total of 15 biopsies were submitted to pathology to distinguish recurrent tumor from scar tissue or necrosis. Moderately-differentiated adenocarcinoma consistent with rectal primary was diagnosed in all core biopsies of the mass and not scar tissue.
Pre-treatment Planning
A posterior CT was performed for pre-treatment planning and 3-D reconstruction. The actual volume of the lesion was 93 cm 3 . The treated target volume was 123 cm 3 , which included 5-10 mm of the fat tissue surrounding the mass. The number of needles spaced 10 mm apart and the number of seeds per needle was calculated. The stereotactic template is large enough to cover a large target and has perforations spaced 2.5 mm apart in either direction for fine needle correction if needed. The dosage was calculated to deliver 200 Gy to the center of the lesion and 150 Gy to the periphery.
3-D CT-Guided Implant Procedure
Prior to treatment, the patient voided and a Foley catheter was placed in the urinary bladder. The procedure was performed under epidural anesthesia with the patient in prone position and a 10-cm pad placed under his pelvis with feet first towards the gantry. The CT gantry was tilted at 26 degrees (negative). The template attached to the stereotactic device was also angled at 26 degrees to match the gantry angle. The template was also adjusted to avoid needle penetration of the sacrum (Figure 3) . The table index measured 5.5 mm and the thickness of the slice at 5 mm. Five-millimeter tomographic cuts were obtained of the pelvic mass. A 10-mm electronic square grid is superimposed on every second image. The number of needles to be placed throughout the target 10 mm apart, the depth of penetration, and the number of seeds per needle were calculated using these CT grid images and recorded on a summary chart. Precise placement of the afterloading needles is achieved with the 3dimensional stereotactic system and correct position of needle placement is verified with CT prior to the implant.
A total of 60 afterloading needles were inserted through the template 10 mm apart in the predetermined depth in the pelvic mass. A Mick applicator was used for loose seeds. The afterloading needles were not preloaded to avoid seed placement in vessels and keep seed migration to a minimum. Three hundred thirty three (333) Tumor is outlined in red. The 100% isosdose level is outlined in pink. The 50% isodose level is outlined in yellow. Green dot represents the urethra, which is spared from seed placement.
Figure 6:
Post-implant CT dosimetry of midportion of lesion taken immediately after implant. Tumor is outlined in red. The 100% isosdose level is outlined in pink. The 50% isodose level is outlined in yellow. Green dot represents the urethra, which is spared from seed placement.
Figure 7:
Post-implant CT dosimetry of presacral mass taken immediately after implant. Tumor is outlined in red. The 100% isosdose level is outlined in pink. The 50% isodose level is outlined in yellow.
target (Figure 4) , with a dosage of 150 Gy to the periphery and 200 Gy to the center as calculated by post-implant CT dosimetry with Varian MMS software. (Figures 5-7) . The entire procedure lasted for two hours. The patient left the facility ambulatory, in good condition one hour following the implant.
Good coverage of the entire target, including the portion anterior of the sacrum and coccyx, was achieved. (See Figure 7) . Seed placement in the adjacent vital structures (prostatic urethra, urinary bladder, and bowels) was spared. Patient returned to work 3 days after the implant and patient had no acute symptoms during 4 months after implant. The patient had no pain requiring medication 3 weeks after implant. The biochemical response has been favorable. His CEA level decreased from 67 ng/ml prior to implant to 20 ng/ml 4 weeks after implant, 9 ng/ml at 8 weeks, and to 5.2 ng/ml at 8 months.
Discussion
Three-dimensional stereotactic needle placement throughout the human body and the use of CT to determine the ideal needle path has been reported by the senior author (3). Since 1994 we have used the stereotactic system for CT-guided core biopsies and for primary interstitial radiation of localized prostate cancer. (4, 5). We have successfully performed interstitial radiation implant to treat prostate cancer patients who had no rectums because of previous radical surgery for colorectal cancer. The 3-D stereotactic template allows for precise CT-guided needle placement of one or more needles into the target. Brachytherapy sources with a high dose of interstitial radiation can be used successfully in radioresistant tumors in patients who do not respond to the usual permissible dosage of external beam radiation therapy. This is the first time we have used the 3-D stereotactic CTguided interstitial radiation method for the treatment of locally-recurring nonresectable large volume colorectal cancer after failed radical colectomy and radical radiation therapy and chemotherapy. The patient's clinical and biochemical results were excellent. The CEA decreased from 67 ng/mL to 5.7 ng/mL in 12 months after implant. The tumor regressed considerably as identified by CT 10 months after implant. The patient remained asymptomatic. The clinical and biochemical results of this salvage brachytherapy of locally-recurring nonresectable colorectal cancer are very encouraging; however, long-term data in a greater universe of patients are required.
